Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls
about
Alkaline ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides, and its down-regulation inhibits both cell proliferation and apoptosisAlkaline ceramidase 2 (ACER2) and its product dihydrosphingosine mediate the cytotoxicity of N-(4-hydroxyphenyl)retinamide in tumor cellsAn overview of sphingolipid metabolism: from synthesis to breakdownCeramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphateAlkaline Ceramidase 3 Deficiency Results in Purkinje Cell Degeneration and Cerebellar Ataxia Due to Dyshomeostasis of Sphingolipids in the BrainRole of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes.Acid ceramidase (ASAH1) is a global regulator of steroidogenic capacity and adrenocortical gene expressionDownregulation of neutral ceramidase by gemcitabine: Implications for cell cycle regulation.Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis.Sphingolipids in the DNA damage response.Increased acid ceramidase expression depends on upregulation of androgen-dependent deubiquitinases, USP2, in a human prostate cancer cell line, LNCaP.A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease.Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases.C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease.The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber disease.Farber's disease: a fine structural study.
P2860
Q24294788-B813C98A-6B28-48ED-B562-42A699B4D5B0Q24338765-F41CE1AF-4F8A-4C5D-B2EA-DE4EB3AFCCDEQ24628769-6ABC8E2C-7E2B-40C4-AD49-6249BE8E3D45Q24653552-654578A0-31A8-47C8-ACB1-E69A9FCFDB47Q27310161-8DBD903F-D35A-4230-803B-147AA01B07F7Q33919511-AFB9BCB4-2D4E-4867-B779-7D60D911A667Q35744011-C3D7479A-84A7-44AF-8900-ACC18F79481CQ37458377-B031C49E-A214-414B-999C-38510447888FQ37997376-B0818BFC-69B0-45B4-A985-DA1444455177Q38272799-11209804-885A-489E-B0C2-EB5897741757Q38885436-D035EABA-15D3-4A4C-8ACB-143A4C7B4D42Q39651519-6C0D660D-C3A9-4853-A316-717813C1E827Q40158736-A79E3D8F-DEBB-4966-AD75-07EF863208DBQ41094126-6F11B8B2-D009-49AA-96F2-03D44C8B940DQ41533061-5808B4FF-FD43-4D72-8949-C5E9326F06E8Q44176550-A04921BB-1D9C-4EEE-90BB-6C80DEF3F6D6
P2860
Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls
description
1982 nî lūn-bûn
@nan
1982 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
name
Substrate-specificities of aci ...... th Farber disease and controls
@ast
Substrate-specificities of aci ...... th Farber disease and controls
@en
Substrate-specificities of aci ...... th Farber disease and controls
@nl
type
label
Substrate-specificities of aci ...... th Farber disease and controls
@ast
Substrate-specificities of aci ...... th Farber disease and controls
@en
Substrate-specificities of aci ...... th Farber disease and controls
@nl
prefLabel
Substrate-specificities of aci ...... th Farber disease and controls
@ast
Substrate-specificities of aci ...... th Farber disease and controls
@en
Substrate-specificities of aci ...... th Farber disease and controls
@nl
P2093
P2860
P356
P1433
P1476
Substrate-specificities of aci ...... th Farber disease and controls
@en
P2093
P2860
P304
P356
10.1042/BJ2050419
P407
P577
1982-08-01T00:00:00Z